However, the LYVE-1 density at each hotspot area along the TS displayed no significant difference between CLL- and PBSL-treated groups after 7 days post-CLL (Figure 2C), potentially because of the shared marker of LYVE-1 between MLVs and LYVE-1+ macrophages. The gene discussed is LYVE1; the disease is B-cell chronic lymphocytic leukemia.